<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517179</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2006.017-T</org_study_id>
    <secondary_id>HARECCTR0500057</secondary_id>
    <nct_id>NCT00517179</nct_id>
  </id_info>
  <brief_title>Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS</brief_title>
  <official_title>Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS for the Treatment of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the interaction between doxazosin GITS and
      vardenafil on blood pressure (Both systolic and diastolic blood pressure) in patients with
      both ED and BPH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maximal change of the standing systolic blood pressure (SBP) from half hour prior to till six hour after administration of the drug (baseline) with vardenafil administration versus placebo</measure>
    <time_frame>From half hour prior to till six hour after administration of the drug (baseline)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean maximal post-baseline change of the standing and supine diastolic blood pressure (DBP)</measure>
    <time_frame>From half hour prior to till six hour after administration of the drug (baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean maximal post-baseline change supine SBP, and (3) the pattern of changes of the SBP and DBP from half hour prior to till six hours after administration of the drug</measure>
    <time_frame>From half hour prior to till six hour after administration of the drug (baseline)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Impotence</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vardenafil 10mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 50 to 80 years old

          -  Clinically diagnosed to have lower urinary tract symptoms secondary to BPH:

               1. Suffered from lower urinary tract symptoms with International Prostate Symptom
                  Score (IPSS) &gt;=8

               2. Detectable prostatic enlargement determined by Digital Rectum Examination (DRE)

               3. Urinary flow between 5 to 15ml/second in a total void volume &gt;=150mL

          -  Currently on regular doxazosin GITS once-daily for at least 4 weeks without clinically
             significant side effects

          -  Complaints of erectile dysfunction with Erectile Function domain (EF) of the
             International Index of Erectile Function (IIEF) score &lt;= 21

        Exclusion Criteria:

          -  Congestive heart failure, unstable angina, arrhythmia, myocardial infraction

          -  Hypertension or on any antihypertensive agents

          -  Take nitrate and medication contradicted to vardenafil

          -  Uncontrolled or poorly controlled diabetes mellitus

          -  Intolerance or contra-indicated for the use of vardenafil

          -  Hepatic disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chi Fai Ng, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Division of Urology, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <keyword>Benign Prostatic Hyperplasia (BPH)</keyword>
  <keyword>Erectile Dysfunction (ED)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

